Intuitive Surgical Stock Has Been Hit Hard in 2026. Is It Finally Time to Buy?

Intuitive Surgical reported Q1 2026 revenue of $2.77 billion, up 23% year over year, while worldwide procedures rose 17% and adjusted EPS jumped 38%. Management raised full-year da Vinci procedure growth guidance to 13.5% to 15.5%, and recurring revenue reached 86% of sales, though China competition, GLP-1 pressure on bariatric procedures, and tariff/freight costs remain headwinds. The article argues OpenAI's robotics push is unlikely to threaten the company's surgical moat in the near term despite the stock's roughly 26% decline in 2026.

Analysis

The market is treating the AI-robotics headline as if it changes the competitive set for soft-tissue surgery, but that is a category error. The more important second-order effect is that the selloff has reset expectations so far that the stock is now trading on fear of a future moat break rather than on current operating momentum; that tends to create bad entry points for shorts and good entry points for patient longs.

The real earnings engine is not procedure growth alone, but mix and consumables intensity. As newer systems penetrate the base, the company can still grow faster than procedure counts even if volume decelerates modestly, because per-case economics and installed-base monetization do the heavy lifting. That makes near-term downside more likely to come from cost inflation and country-level reimbursement pressure than from a sudden demand collapse.

China remains the clearest tactical risk, but it is more of a margin and sentiment overhang than a thesis breaker. The more subtle threat is not direct displacement in the next 12 months, but domestic competitors using tender wins as proof points to pressure pricing globally and force procurement committees to demand concessions. If that narrative gains traction, it could cap multiple expansion even if U.S. growth stays intact.

Consensus is underestimating how long it would take for any AI-native entrant to clear the clinical evidence, regulatory, workflow integration, and surgeon-training hurdles in this niche. The flip side is that valuation leaves very little cushion if growth normalizes or if tariffs/freight/memory costs persist for multiple quarters. In other words, the stock is probably not broken, but it is vulnerable to being a great company at an unhelpful price unless execution stays clean through the next several prints.

Key Decisions for Investors

• Buy ISRG on further weakness only, preferably into a flush toward prior lows over the next 1-4 weeks; risk/reward improves if the stock re-rates to a lower-teens FCF yield while operating momentum remains intact.
• Do not short ISRG outright here; if bearish, use a defined-risk put spread for 3-6 months out, because the current narrative can unwind quickly if guidance or procedure growth holds up.
• Pair trade: long ISRG / short a basket of Chinese medtech or domestic robotics proxies if available, as the market is likely overpricing direct AI disruption versus underpricing U.S. installed-base resilience over the next 6-12 months.
• If already long ISRG, consider selling out-of-the-money covered calls against a starter position to monetize elevated volatility while capping upside in a valuation-sensitive name.
• Set a catalyst watch for the next quarterly print: if procedure growth decelerates but revenue per procedure and margin expansion stay firm, maintain the long; if both soften together, cut exposure quickly because the multiple will compress fast.